SCHEMBL16604750

SCHEMBL16604750

O=C(NC1CCC(N2CCC(O)CC2)CC1)OCc1ccccc1

nearest known ligand 0.63

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.63
GAA P10253 1/20 0.63
TSHR P16473 1/20 0.60
DPP4 P27487 7/20 0.55
DPP7 Q9UHL4 7/20 0.55
KCNH2 Q12809 4/20 0.55
CTSL P07711 1/20 0.55
CTSB P07858 1/20 0.55
CTSK P43235 1/20 0.55
EPHX1 P07099 1/20 0.54
JAK2 O60674 1/20 0.48
JAK1 P23458 1/20 0.48
TYK2 P29597 1/20 0.48
HSD11B1 P28845 1/20 0.47
MEN1 O00255 1/20 0.47
KMT2A Q03164 1/20 0.47
F13A1 P00488 1/20 0.47
TGM2 P21980 1/20 0.47
TGM1 P22735 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16604745 1.00 ALDH1A1 (0.63) ALDH1A1GAATSHRDPP4DPP7
SCHEMBL19562716 0.93 ALDH1A1 (0.60) ALDH1A1GAATSHRDPP4DPP7
SCHEMBL851220 0.87 ALDH1A1 (0.76) ALDH1A1GAATSHRDPP4DPP7
SCHEMBL761181 0.87 ALDH1A1 (0.76) ALDH1A1GAATSHRDPP4DPP7
SCHEMBL9555876 0.87 ALDH1A1 (0.76) ALDH1A1GAATSHRDPP4DPP7
SCHEMBL854004 0.87 ALDH1A1 (0.62) ALDH1A1GAATSHRDPP4DPP7
SCHEMBL15873821 0.86 ALDH1A1 (0.60) ALDH1A1GAATSHRDPP4DPP7
SCHEMBL15873777 0.86 ALDH1A1 (0.60) ALDH1A1GAATSHRDPP4DPP7
SCHEMBL28356284 0.85 TSHR (0.60) ALDH1A1GAATSHRDPP4DPP7
SCHEMBL28356285 0.85 TSHR (0.60) ALDH1A1GAATSHRDPP4DPP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170035766-A1 IRAK INHIBITORS AND USES THEREOF NIMBUS IRIS INC (US) 2017-02-09 US disclosed
US-20170035766-A1 IRAK INHIBITORS AND USES THEREOF NIMBUS IRIS INC (US) 2017-02-09 US disclosed
US-9518065-B2 IRAK inhibitors and uses thereof NIMBUS IRIS, INC. (US) 2016-12-13 US disclosed
US-9518065-B2 IRAK inhibitors and uses thereof NIMBUS IRIS, INC. (US) 2016-12-13 US disclosed
US-20150094305-A1 IRAK INHIBITORS AND USES THEREOF NIMBUS IRIS, INC. 2015-04-02 US disclosed
US-20150094305-A1 IRAK INHIBITORS AND USES THEREOF NIMBUS IRIS, INC. 2015-04-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170035766-A1 IRAK INHIBITORS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 4076/4885GAA 2969/4885TSHR 3940/4885
US-20150094305-A1 IRAK INHIBITORS AND USES THEREOF IRAK2, IRAK3, IRAK1 ALDH1A1 4076/4885GAA 2969/4885TSHR 3940/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.